Charles Schwab’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Charles Schwab’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-24	Closed	-$45K	–	3595
2021 Q1	$45K	Buy	+24	New	+$48K	﹤0.01%	3446
2020 Q2	–	Sell	-14	Closed	-$48K	–	3382
2020 Q1	$48K	Hold	14	–	–	﹤0.01%	3163
2019 Q4	$133K	Buy	+14	New	+$119K	﹤0.01%	3078

Other funds holding BXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Charles Schwab's BXRX Position: Q2 2021 in Review

Charles Schwab sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2021, closing a stake of 24 shares — an estimated $45K sold.

Charles Schwab first reported a position in BXRX in Q4 2019 and held it in 3 quarters. The position peaked at $133K in Q4 2019. 31 funds tracked by Wall St. Rank hold BXRX as of Q2 2021.

Charles Schwab reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Charles Schwab sold 24 Baudax Bio, Inc. Common Stock shares in Q2 2021, an estimated $45K.
Charles Schwab first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Charles Schwab's Baudax Bio, Inc. Common Stock position peaked at $133K in Q4 2019.
31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.